Dyson, Paul J.2008-03-092008-03-092008-03-09200710.2533/chimia.2007.698https://infoscience.epfl.ch/handle/20.500.14299/19922WOS:00025151340000311683Organometallic ruthenium compds. that are effective anticancer and antimetastasis agents are currently under intensive investigation (see also the article by Peter Sadler in this issue). This article provides a personal account of the way in which we have exploited the different properties of the organoruthenium (and osmium and rhodium) compds. to rival traditional DNA-binding platinum drugs, culminating in the discovery of a non-classical mol. that is in an advanced stage of pre-clin. evaluation.text::journal::journal article::research article